首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >PREPARATION AND PROPERTIES OF NIDO-CARBORANE-SPECIFIC MONOCLONAL ANTIBODIES FOR POTENTIAL USE IN BORON NEUTRON CAPTURE THERAPY FOR CANCER
【24h】

PREPARATION AND PROPERTIES OF NIDO-CARBORANE-SPECIFIC MONOCLONAL ANTIBODIES FOR POTENTIAL USE IN BORON NEUTRON CAPTURE THERAPY FOR CANCER

机译:硼中子俘获治疗中潜在使用的尼多甲硼烷特定单克隆抗体的制备及性能

获取原文
获取原文并翻译 | 示例
       

摘要

As the first step of a research program aimed at developing a bispecific monoclonal antibody system for the delivery of boron-rich molecules to tumor cells for boron neutron capture therapy, monoclonal antibodies (mAbs) were produced against an anionic nido-carborane derivative, 4-[7,8-dicarbadodecahydroundecaborat(-1)-7-yl]butanoic acid. Two IgG subclass mAbs, designated HAW101 and HAW102, were identified that specifically bound the anionic nido-carborane hapten, as well as a variety of other anionic nido-carborane cage derivatives, By using surface plasmon resonance technology, the affinity constants of HAW101 and HAW102 were determined to be 1.9 x 10(9) and 6.8 x 10(8) M(-1), respectively. A diverse array of 7-substituted and 7,8-disubstituted anionic nido-carborane derivatives reacted with the mAb HAW101 in competition ELISA, whereas anionic closo-polyhedral boranes showed negligible binding, suggesting a role for the open nido-carborane cage structure. These results suggest that mAbs such as HAW101, which bind anionic nido-carboranes, are useful in the development of bispecific mAbs for specific targeting and enhanced boron delivery to tumor sites. [References: 32]
机译:作为旨在开发双特异性单克隆抗体系统以将富硼分子递送至肿瘤细胞以进行硼中子俘获治疗的研究计划的第一步,已生产出针对阴离子型Nido-carborane衍生物4的单克隆抗体(mAb)。 [7,8-二氨基十二碳六氢十一溴(-1)-7-基]丁酸。通过使用表面等离振子共振技术,鉴定了两种IgG亚类mAb,分别命名为HAW101和HAW102,它们特异性结合了阴离子型Nido-Carbane半抗原和多种其他阴离子型Nano-Carbane笼衍生物。HAW101和HAW102的亲和常数分别确定为1.9 x 10(9)和6.8 x 10(8)M(-1)。在竞争ELISA中,各种各样的7-取代和7,8-二取代阴离子nido-carborane衍生物与mAb HAW101反应,而阴离子closo-多面体硼烷显示出微不足道的结合力,提示了开放的nido-carborane笼结构的作用。这些结果表明,结合阴离子nido-carboranes的mAbs,例如HAW101,可用于开发双特异性mAbs,以进行特异性靶向和增强硼向肿瘤部位的递送。 [参考:32]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号